Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.55 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18280283 | 0.81 | TNF (0.63) | TNFAURKAPDE4BPDE4DHPGD | |
| SCHEMBL18280281 | 0.78 | TNF (0.68) | TNFPDE4BPDE4DRXRANR4A2 | |
| SCHEMBL18280291 | 0.78 | TNF (0.64) | TNFAURKAPDE4BPDE4DRAB9A | |
| SCHEMBL15055239 | 0.78 | TNF (0.60) | TNFPDE4BPDE4DNPC1RAB9A | |
| SCHEMBL15055192 | 0.78 | TNF (0.62) | TNFPDE4BPDE4DHPGDNPC1 | |
| Bromide SCHEMBL15055004 | 0.76 | TNF (0.61) | TNFPDE4BPDE4DHPGDNPC1 | |
| SCHEMBL18280290 | 0.76 | TNF (0.57) | TNFPDE4BPDE4D | |
| SCHEMBL18280288 | 0.76 | TNF (0.57) | TNFAURKAHPGDNPC1RAB9A | |
| SCHEMBL15055818 | 0.72 | TNF (0.53) | TNFHPGDRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3423042 | 0.71 | LPL (0.48) | HPGDSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9889139-B2 | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2018-02-13 | — | — | US | claimed |
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2016-12-08 | — | — | US | claimed |
| US-9889139-B2 | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2018-02-13 | — | — | US | disclosed |
| US-9889139-B2 | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2018-02-13 | — | — | US | disclosed |
| US-9889139-B2 | Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2018-02-13 | — | — | US | disclosed |
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354352-A1 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT | SI, SLC10A2, ALPI | TNF 100/4885AURKA 4625/4885PDE4B 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.